BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 27,389 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 27,389 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $613,787.49. Following the completion of the sale, the chief executive officer now owns 4,897,443 shares in the company, valued at approximately $109,751,697.63. This represents a 0.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

BridgeBio Pharma Stock Up 0.8 %

BridgeBio Pharma stock opened at $23.42 on Friday. The company has a fifty day simple moving average of $24.96 and a 200-day simple moving average of $26.26. The firm has a market capitalization of $4.43 billion, a price-to-earnings ratio of -9.72 and a beta of 1.09. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $44.32.

Wall Street Analyst Weigh In

Several research firms recently commented on BBIO. Cantor Fitzgerald restated an “overweight” rating and set a $70.00 price target on shares of BridgeBio Pharma in a research report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $43.00 price target on shares of BridgeBio Pharma in a research note on Friday, October 25th. JPMorgan Chase & Co. lowered their price target on BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Oppenheimer began coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a “market perform” rating for the company. Finally, Scotiabank increased their target price on BridgeBio Pharma from $44.00 to $45.00 and gave the company a “sector outperform” rating in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $47.57.

Institutional Trading of BridgeBio Pharma

Hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its position in shares of BridgeBio Pharma by 22.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 803,956 shares of the company’s stock valued at $24,859,000 after purchasing an additional 145,594 shares in the last quarter. Vanguard Group Inc. grew its holdings in BridgeBio Pharma by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 13,222,126 shares of the company’s stock valued at $408,828,000 after buying an additional 421,832 shares in the last quarter. First Turn Management LLC purchased a new stake in BridgeBio Pharma in the 3rd quarter valued at $10,178,000. Comerica Bank increased its stake in shares of BridgeBio Pharma by 3,013.5% in the 1st quarter. Comerica Bank now owns 38,514 shares of the company’s stock worth $1,191,000 after acquiring an additional 37,277 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. raised its holdings in shares of BridgeBio Pharma by 6.4% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,632,604 shares of the company’s stock worth $92,014,000 after acquiring an additional 217,000 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.